SEC Info - Cytrx Corp - ‘10-K’ for 12/31/12

SEC Info℠

Home

Help

Please Sign In

Cytrx Corp – ‘10-K’ for 12/31/12 – ‘EX-31.2’

On: Monday, 3/11/13, at 8:29am ET · For: 12/31/12 · Accession #: 799698-13-5 · File #: 0-15327

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/11/13  Cytrx Corp                        10-K       12/31/12   68:8.6M

Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Form 10-K for Year Ended December 31, 2012          HTML   1.18M 
 2: EX-4.8      Restricted Stock Purchase Agreement Dated December  HTML     45K 
                31, 2012, Between Cytrx Corporation and Daniel                   
                Levitt, M.D., Ph.D.                                              
 3: EX-10.19    Employment Agreement Dated January 1, 2013,         HTML     61K 
                Between Cytrx Corporation and Daniel Levitt, M.D.                
                Ph.D.                                                            
 4: EX-10.20    Employment Agreement Dated January 1, 2013,         HTML     51K 
                Between Cytrx Corporation and Benjamin S. Levin                  
 5: EX-10.21    Employment Agreement Dated January 1, 2013,         HTML     51K 
                Between Cytrx Corporation and Scott Wieland                      
 6: EX-10.22    Employment Agreement Dated January 1, 2013,         HTML     51K 
                Between Cytrx Corporation and John Y. Caloz                      
 7: EX-23.1     Consent of Experts or Counsel                       HTML     20K 
 8: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 9: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
10: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
11: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
48: R1          Document and Entity Information                     HTML     48K 
38: R2          Consolidated Balance Sheets                         HTML    111K 
46: R3          Consolidated Balance Sheets (Parenthetical)         HTML     50K 
50: R4          Consolidated Statements of Operations               HTML     85K 
63: R5          Consolidated Statements of Stockholders' Equity     HTML     75K 
40: R6          Consolidated Statements of Cash Flows               HTML    141K 
45: R7          Nature of Business                                  HTML     27K 
35: R8          Summary of Significant Accounting Policies          HTML     66K 
27: R9          Receivables                                         HTML     25K 
64: R10         Prepaid and Other Assets                            HTML     22K 
52: R11         Short-term Investments                              HTML     27K 
51: R12         Equipment and Furnishings                           HTML     31K 
56: R13         Accrued Expenses and Other Current Liabilities      HTML     30K 
57: R14         Warrant Liabilities                                 HTML     35K 
55: R15         Commitments and Contingencies                       HTML     45K 
58: R16         Equity Transactions                                 HTML     36K 
47: R17         Investments in ADVENTRX Pharmaceuticals             HTML     25K 
49: R18         Stock Options and Warrants                          HTML    212K 
54: R19         Sale of Assets                                      HTML     23K 
68: R20         Stockholder Protection Rights Plan                  HTML     25K 
60: R21         Income Taxes                                        HTML     61K 
42: R22         Quarterly Financial Data (Unaudited)                HTML     49K 
53: R23         Schedule Ii - Valuation and Qualifying Accounts     HTML     43K 
44: R24         Summary of Significant Accounting Policies          HTML    136K 
                (Policies)                                                       
23: R25         Summary of Significant Accounting Policies          HTML     39K 
                (Tables)                                                         
61: R26         Equipment and Furnishings (Tables)                  HTML     29K 
65: R27         Accrued Expenses and Other Current Liabilities      HTML     29K 
                (Tables)                                                         
31: R28         Commitments and Contingencies (Tables)              HTML     34K 
30: R29         Stock Options and Warrants (Tables)                 HTML    214K 
33: R30         Income Taxes (Tables)                               HTML     54K 
34: R31         Quarterly Financial Data (Unaudited) (Tables)       HTML     45K 
36: R32         Nature of Business (Details)                        HTML     43K 
21: R33         Summary of Significant Accounting Policies          HTML     66K 
                (Details)                                                        
59: R34         Receivables (Details)                               HTML     22K 
41: R35         Prepaid and Other Assets (Details)                  HTML     22K 
43: R36         Short-term Investments (Details)                    HTML     29K 
25: R37         Equipment and Furnishings (Details)                 HTML     36K 
67: R38         Accrued Expenses and Other Current Liabilities      HTML     36K 
                (Details)                                                        
18: R39         Warrant Liabilities (Details)                       HTML     25K 
37: R40         Commitments and Contingencies (Details)             HTML     80K 
62: R41         Equity Transactions (Details)                       HTML     53K 
24: R42         Investments in ADVENTRX Pharmaceuticals (Details)   HTML     33K 
29: R43         Stock Options and Warrants (Details)                HTML    311K 
32: R44         Sale of Assets (Details)                            HTML     24K 
39: R45         Stockholder Protection Rights Plan (Details)        HTML     32K 
20: R46         Income Taxes (Details)                              HTML    108K 
26: R47         Quarterly Financial Data (Unaudited) (Details)      HTML     39K 
19: R48         Schedule Ii - Valuation and Qualifying Accounts     HTML     31K 
                (Details)                                                        
66: XML         IDEA XML File -- Filing Summary                      XML     94K 
28: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.08M 
12: EX-101.INS  XBRL Instance -- cytr-20121231                       XML   1.66M 
14: EX-101.CAL  XBRL Calculations -- cytr-20121231_cal               XML    172K 
15: EX-101.DEF  XBRL Definitions -- cytr-20121231_def                XML    375K 
16: EX-101.LAB  XBRL Labels -- cytr-20121231_lab                     XML   1.45M 
17: EX-101.PRE  XBRL Presentations -- cytr-20121231_pre              XML    780K 
13: EX-101.SCH  XBRL Schema -- cytr-20121231                         XSD    151K 
22: ZIP         XBRL Zipped Folder -- 0000799698-13-000005-xbrl      Zip    149K

‘EX-31.2’ — Certification — §302 – SOA’02

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

C: C: C:

EXHIBIT 31.2

CERTIFICATIONS

I, John Y. Caloz, Chief Financial Officer of CytRx Corporation, certify that:

1. I have reviewed this annual report on Form 10-K of CytRx Corporation;

2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this annual report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the periods covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 11, 2013	By:	/s/ *JOHN Y. CALOZ*
		John Y. Caloz
		Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-K’ Filing	Date	Other Filings

Filed on:	3/11/13	8-K
For Period end:	12/31/12	4, 4/A, 8-K
		List all Filings

↑Top

Filing Submission 0000799698-13-000005 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)